Exact Mass: 197.0486
Exact Mass Matches: 197.0486
Found 500 metabolites which its exact mass value is equals to given mass value 197.0486,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
L-Dopa
L-dopa is an optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinsons disease It has a role as a prodrug, a hapten, a neurotoxin, an antiparkinson drug, a dopaminergic agent, an antidyskinesia agent, an allelochemical, a plant growth retardant, a human metabolite, a mouse metabolite and a plant metabolite. It is a dopa, a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-dopa(1-). It is an enantiomer of a D-dopa. It is a tautomer of a L-dopa zwitterion. Levodopa is a prodrug of dopamine that is administered to patients with Parkinsons due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinsons. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975. 3,4-Dihydroxy-L-phenylalanine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Levodopa is an Aromatic Amino Acid. Levodopa is an amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinsons disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS. L-Dopa is used for the treatment of Parkinsonian disorders and Dopa-Responsive Dystonia and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Peripheral tissue conversion may be the mechanism of the adverse effects of levodopa. It is standard clinical practice to co-administer a peripheral DOPA decarboxylase inhibitor - carbidopa or benserazide - and often a catechol-O-methyl transferase (COMT) inhibitor, to prevent synthesis of dopamine in peripheral tissue.The naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. [PubChem]L-Dopa is the naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. Unlike dopamine itself, L-Dopa can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. In particular, it is metabolized to dopamine by aromatic L-amino acid decarboxylase. Pyridoxal phosphate (vitamin B6) is a required cofactor for this decarboxylation, and may be administered along with levodopa, usually as pyridoxine. The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside ... L-DOPA, also known as levodopa or 3,4-dihydroxyphenylalanine is an alpha amino acid. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon). L-DOPA is found naturally in both animals and plants. It is made via biosynthesis from the amino acid L-tyrosine by the enzyme tyrosine hydroxylase.. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. The Swedish scientist Arvid Carlsson first showed in the 1950s that administering L-DOPA to animals with drug-induced (reserpine) Parkinsonian symptoms caused a reduction in the intensity of the animals symptoms. Unlike dopamine itself, L-DOPA can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. In particular, it is metabolized to dopamine by aromatic L-amino acid decarboxylase. Pyridoxal phosphate (vitamin B6) is a required cofactor for this decarboxylation, and may be administered along with levodopa, usually as pyridoxine. As a result, L-DOPA is a drug that is now used for the treatment of Parkinsonian disorders and DOPA-Responsive Dystonia. It is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. It is standard clinical practice in treating Parkinsonism to co-administer a peripheral DOPA decarboxylase inhibitor - carbidopa or benserazide - and often a catechol-O-methyl transferase (COMT) inhibitor, to prevent synthesis of dopamine in peripheral tissue. Side effects of L-DOPA treatment may include: hypertension, arrhythmias, nausea, gastrointestinal bleeding, disturbed respiration, hair loss, disorientation and confusion. L-DOPA can act as an L-tyrosine mimetic and be incorporated into proteins by mammalian cells in place of L-tyrosine, generating protease-resistant and aggregate-prone proteins in vitro and may contribute to neurotoxicity with chronic L-DOPA administration. L-phenylalanine, L-tyrosine, and L-DOPA are all precursors to the biological pigment melanin. The enzyme tyrosinase catalyzes the oxidation of L-DOPA to the reactive intermediate dopaquinone, which reacts further, eventually leading to melanin oligomers. An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinsons disease DOPA. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=59-92-7 (retrieved 2024-07-01) (CAS RN: 59-92-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). DL-Dopa is a beta-hydroxylated derivative of phenylalanine. DL-Dopa is a beta-hydroxylated derivative of phenylalanine.
N-Acetylhistidine
N-Acetyl-L-histidine or N-Acetylhistidine, belongs to the class of organic compounds known as N-acyl-alpha amino acids. N-acyl-alpha amino acids are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. N-Acetylhistidine can also be classified as an alpha amino acid or a derivatized alpha amino acid. Technically, N-Acetylhistidine is a biologically available N-terminal capped form of the proteinogenic alpha amino acid L-histidine. N-acetyl amino acids can be produced either via direct synthesis of specific N-acetyltransferases or via the proteolytic degradation of N-acetylated proteins by specific hydrolases. N-terminal acetylation of proteins is a widespread and highly conserved process in eukaryotes that is involved in protection and stability of proteins (PMID: 16465618). About 85\\% of all human proteins and 68\\% of all yeast proteins are acetylated at their N-terminus (PMID: 21750686). Several proteins from prokaryotes and archaea are also modified by N-terminal acetylation. The majority of eukaryotic N-terminal-acetylation reactions occur through N-acetyltransferase enzymes or NAT’s (PMID: 30054468). These enzymes consist of three main oligomeric complexes NatA, NatB, and NatC, which are composed of at least a unique catalytic subunit and one unique ribosomal anchor. The substrate specificities of different NAT enzymes are mainly determined by the identities of the first two N-terminal residues of the target protein. The human NatA complex co-translationally acetylates N-termini that bear a small amino acid (A, S, T, C, and occasionally V and G) (PMID: 30054468). NatA also exists in a monomeric state and can post-translationally acetylate acidic N-termini residues (D-, E-). NatB and NatC acetylate N-terminal methionine with further specificity determined by the identity of the second amino acid. N-acetylated amino acids, such as N-acetylhistidine can be released by an N-acylpeptide hydrolase from peptides generated by proteolytic degradation (PMID: 16465618). In addition to the NAT enzymes and protein-based acetylation, N-acetylation of free histidine can also occur. In particular, N-Acetylhistidine can be biosynthesized from L-histidine and acetyl-CoA by the enzyme histidine N-acetyltransferase (EC 2.3.1.33). Many N-acetylamino acids are classified as uremic toxins if present in high abundance in the serum or plasma (PMID: 26317986; PMID: 20613759). Uremic toxins are a diverse group of endogenously produced molecules that, if not properly cleared or eliminated by the kidneys, can cause kidney damage, cardiovascular disease and neurological deficits (PMID: 18287557). Constituent of the tissues of various fish and amphibian subspecies N-Acetylhistidine is found in fishes. KEIO_ID A073
N-Hydroxy-L-tyrosine
Biosynthetic intermediate of dhurrin in Sorghum bicolor (sorghum). N-Hydroxy-L-tyrosine is found in many foods, some of which are allspice, asparagus, lemon thyme, and sparkleberry. N-Hydroxy-L-tyrosine is found in cereals and cereal products. Biosynthetic intermediate of dhurrin in Sorghum bicolor (sorghum).
Phosphoguanidinoacetate
Phosphoguanidinoacetate is formed due to phosphorylation of urinary guanidinoacetic acid in the presence of ATP by guanidinoacetate kinase. (PMID: 1667626) [HMDB] Phosphoguanidinoacetate is formed due to phosphorylation of urinary guanidinoacetic acid in the presence of ATP by guanidinoacetate kinase. (PMID: 1667626).
3-Hydroxy-2-methylpyridine-4,5-dicarboxylate
3-Hydroxy-2-methylpyridine-4,5-dicarboxylate is an intermediate in vitamin B6 metabolism(KEGG ID C04604). It is the third to last step in the synthesis of succinate semialdehyde, which is an intermediate in butanoate metabolism. 3-Hydroxy-2-methylpyridine-4,5-dicarboxylate is generated from 2-Methyl-3-hydroxy-5-formylpyridine-4-carboxylate and is then converted to 3-hydroxy-2-methylpyridine-5-carboxylate. [HMDB] 3-Hydroxy-2-methylpyridine-4,5-dicarboxylate is an intermediate in vitamin B6 metabolism(KEGG ID C04604). It is the third to last step in the synthesis of succinate semialdehyde, which is an intermediate in butanoate metabolism. 3-Hydroxy-2-methylpyridine-4,5-dicarboxylate is generated from 2-Methyl-3-hydroxy-5-formylpyridine-4-carboxylate and is then converted to 3-hydroxy-2-methylpyridine-5-carboxylate.
Clavaldehyde
An organic heterobicyclic compound that is clavulanic acid in which the allylic alcohol group has been oxidised to the corresponding aldehyde.
Methyl5-(but-3-en-1-yl)amino-1,3,4-oxadiazole-2-carboxylate
2-Amino-5-phosphonopentanoic acid
DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina[1][2][3].
HC Red 3
CONFIDENCE standard compound; INTERNAL_ID 517; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1613; ORIGINAL_PRECURSOR_SCAN_NO 1611 CONFIDENCE standard compound; INTERNAL_ID 517; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1614; ORIGINAL_PRECURSOR_SCAN_NO 1611 CONFIDENCE standard compound; INTERNAL_ID 517; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1605; ORIGINAL_PRECURSOR_SCAN_NO 1604 CONFIDENCE standard compound; INTERNAL_ID 517; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1619; ORIGINAL_PRECURSOR_SCAN_NO 1617 CONFIDENCE standard compound; INTERNAL_ID 517; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1629; ORIGINAL_PRECURSOR_SCAN_NO 1626 CONFIDENCE standard compound; INTERNAL_ID 517; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1597; ORIGINAL_PRECURSOR_SCAN_NO 1592
2-Hydroxy-3-(3,4-dihydroxyphenyl)propanamide
2-Hydroxy-3-(3,4-dihydroxyphenyl)propanamide is found in herbs and spices. 2-Hydroxy-3-(3,4-dihydroxyphenyl)propanamide is isolated from rhizomes of sage plant. Isolated from rhizomes of sage plant. 2-Hydroxy-3-(3,4-dihydroxyphenyl)propanamide is found in herbs and spices.
DL-Dopa
DL-DOPA, also known as (+-)-DOPA or (R,S)-DOPA or DL-3,4-dihydroxyphenylalanine is an alpha amino acid. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon). DL-DOPA also belongs to the class of organic compounds known as tyrosines and derivatives. Tyrosines and derivatives are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. DL-DOPA is a racemic mixture of both D-DOPA and L-DOPA. D-DOPA is similar to L-DOPA (levodopa), but with opposite chirality. Levo- and dextro- rotation refer to a molecules ability to rotate planes of polarized light in one or the other direction. Whereas L-DOPA is moderately effective in the treatment of Parkinsons disease (PD) by stimulating the production of dopamine in the brain, D-DOPA was at one time thought to be biologically inactive. However, it has recently been found that D-DOPA can be converted to L-DOPA and then to dopamine via the human enzyme known as D-amino acid oxidase and that racemic mixtures of DL-DOPA can be effective in treating Parkinsonism (PMID: 17924443; PMID: 3129126; PMID: 17042912). The biological production or biosynthesis of D-DOPA is thought to occur through bacterial conversion of tyrosine. L-DOPA is found naturally in both animals and plants. It is made via biosynthesis from the amino acid L-tyrosine by the enzyme tyrosine hydroxylase. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. [HMDB] DL-Dopa is a beta-hydroxylated derivative of phenylalanine. DL-Dopa is a beta-hydroxylated derivative of phenylalanine.
N-(4-hydroxyphenyl)ethoxycarbothioamide
N-(4-hydroxyphenyl)ethoxycarbothioamide is found in fats and oils. N-(4-hydroxyphenyl)ethoxycarbothioamide is a constituent of Moringa oleifera (horseradish tree). Constituent of Moringa oleifera (horseradish tree). N-(4-hydroxyphenyl)ethoxycarbothioamide is found in fats and oils, herbs and spices, and green vegetables.
4-hydroxy-3-nitrophenylacetate
4-hydroxy-3-nitrophenylacetate, also known as 3-nitro-4-hydroxyphenylacetic acid, is slightly soluble (in water). It is a mildly acidic compound. This metabolite is a member of the class of compounds known as nitrophenols. Nitrophenols are compounds containing a nitrophenol moiety, which consists of a benzene ring bearing both a hydroxyl group and a nitro group on two different ring carbon atoms. Free nitrotyrosine undergoes metabolism to form 3-nitro-4-hydroxyphenylacetic acid (NHPA) which is excreted in the urine (Wikipedia). However, it is not known whether NHPA is derived exclusively from metabolism of nitrotyrosine, or whether it can be formed by nitration of circulating para -hydroxyphenylacetic acid (PHPA), a metabolite of tyrosine (PMID: 12797864). Since the plasma concentration of PHPA is markedly higher than free nitrotyrosine (approx. 400-fold), the nitration of high-circulating endogenous PHPA to form NHPA becomes very significant and accounts for the majority of NHPA excreted in urine (PMID: 12797864).
Beclamide
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics
vanillyl mandelate
Vanillyl mandelate, also known as 3-methoxy-4-hydroxymandelate or vanilmandelic acid, is a member of the class of compounds known as methoxyphenols. Methoxyphenols are compounds containing a methoxy group attached to the benzene ring of a phenol moiety. Vanillyl mandelate is soluble (in water) and a weakly acidic compound (based on its pKa). Vanillyl mandelate can be found in a number of food items such as brazil nut, feijoa, kiwi, and redcurrant, which makes vanillyl mandelate a potential biomarker for the consumption of these food products. Vanillylmandelic acid (VMA) is a chemical intermediate in the synthesis of artificial vanilla flavorings and is an end-stage metabolite of the catecholamines, epinephrine, and norepinephrine. It is produced via intermediary metabolites .
excavatine C|methyl 2-(1,2-dihydroxyethyl)pyridine-4-carboxylate
2-(4-chloro-[1,3,5]triazin-2-ylamino)-2-methyl-propionitrile
Beclamide
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics
N,N-Acetylhistidine
MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; KBOJOGQFRVVWBH-ZETCQYMHSA-N_STSL_0239_N-Acetylhistidine_0062fmol_190403_S2_LC02MS02_071; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. MS2 deconvoluted using CorrDec from all ion fragmentation data, MetaboLights identifier MTBLS1040; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I.
3,4-Dihydroxy-phenylalanine (L-DOPA); AIF; CE0; MS2Dec
3,4-Dihydroxy-phenylalanine (L-DOPA); AIF; CE10; MS2Dec
3,4-Dihydroxy-phenylalanine (L-DOPA); AIF; CE30; MS2Dec
3-methylhistamine dihydrochloride
3-Methylhistamine dihydrochloride is a degradation product of histamine. 3-Methylhistamine dihydrochloride, a methylated product of histamine, is associated with immune response and shows upregulation in the vaccinated mice[1][2].
3-METHYLPYRROLE-2,4-DICARBOXYLIC ACID DIMETHYL ESTER
4-(chloromethyl)-2-(furan-2-yl)-5-methyl-1,3-oxazole
1H-Benzimidazole-2-methanamine,5,6-difluoro-N-methyl-(9CI)
Methyl 6-amino-2H-thieno[3,2-c]pyrazole-2-carboxylate
D-AP5(mM/ml)
D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors[1][2].
1,3,4-Oxadiazol-2-amine, 5-phenyl-, monohydrochloride
METHYL 3-AMINO-2-HYDROXY-5-METHOXYBENZENECARBOXYLATE
Thiourea, N-ethyl-N-(3-hydroxy-2-pyridinyl)- (9CI)
(1R,2R)-2-amino-1,2-dihydronaphthalen-1-ol,hydrochloride
2-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)acetonitrile
(R)-2,2-DIMETHYLTHIAZOLIDINE-4-CARBOXYLIC ACID HYDROCHLORIDE
(S)-2-AMINO-5-METHOXY-5-OXOPENTANOIC ACID HYDROCHLORIDE
Methyl 2-[5-(3-Phenoxyphenyl)-2H-tetrazol-2-yl]acetate
Ethyl 4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate
2-oxo-6-(2-pyridinyl)-1,2-dihydro-3-pyridinecarbonitrile
ETHYL 4-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIDINE-3-CARBOXYLATE
2,3-DIHYDRO-3,3-DIMETHYL-1,2-BENZISOTHIAZOLE 1,1-DIOXIDE
Cyclopropanecarboxylic acid, 1-[(trifluoroacetyl)amino]- (9CI)
2-(2-Methyl-1H-imidazol-1-yl)ethanamine dihydrochloride
5-hydroxypyridine-3,4-dicarboxylic acid methyl ester
(R)-(-)-α-Methylhistamine dihydrochloride
(R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM[1][2]. (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats[3][4][5].
1-(6-Chloro-pyridin-3-yl)-cyclopropanecarboxylic acid
5-Pyrimidinecarbonitrile, 2-(4-hydroxyphenyl)- (9CI)
(1R)-1-(1H-benzimidazol-2-yl)ethanamine,hydrochloride
Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate
[(2,5-Dimethyl-furan-3-carbonyl)-amino]-acetic acid
9,9-Dimethyl-1-oxa-7-azaspiro[4.4]nonane-2,6,8-trione
1H-Pyrrole-2-aceticacid, 3-(methoxycarbonyl)-, methyl ester
ETHYL 4-HYDROXY-2-METHYL-6-OXO-1,6-DIHYDROPYRIDINE-3-CARBOXYLATE
4-methoxycarbonyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxamide
2-(4-acetyl-5-methyl-2-oxo-1,3-dihydropyrrol-3-yl)acetic acid
N-(methoxymethyl)-1-(trifluoromethyl)cyclopropane-1-carboxamide
1-Methylhistamine dihydrochloride
1-Methylhistamine dihydrochloride is a histamine metabolite[1].
(R)-(-)-α-Methylhistamine dihydrobromide,(R)-(-)-α-Methyl-1H-imidazole-4-ethanaminedihydrobromide
4-amino-4-carboxytetrahydrothiopyran hydrochloride
4-Methylhistamine dihydrochloride
4-Methylhistamine (dihydrochloride) is the potent agonist of histamine 4 receptor (H4R). 4-Methylhistamine (dihydrochloride) has the potential for the research of immune-related diseases such as cancer and autoimmune disorders[1].
2-(4-METHYL-1H-IMIDAZOL-2-YL)-ETHYLAMINE DIHYDROCHLORIDE
Methanone, (4-aminophenyl)cyclopropyl-, hydrochloride
6-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester
6-chloro-2,2-dimethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine
1-(4-methyl-1H-imidazol-2-yl)ethanamine(SALTDATA: 1.95HCl 0.5H2O 0.15NaCl)
3,6-Dihydro-3-methyl-5-(methylthio)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one
[(1,2-Dimethyl-1H-imidazol-5-yl)methyl]amine dihydrochloride
Methyl 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate
2-(2-Chloroethyl)-1-methylpiperidine hydrochloride
2-(carboxymethyl)-1,4-dimethylpyrrole-3-carboxylic acid
2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid
2-{[4-(4-FLUOROPHENYL)-6-(TRIFLUOROMETHYL)-PYRIMIDIN-2-YL]THIO}PROPANOIC ACID
3-Pyridinecarboxylicacid,6-[(aminothioxomethyl)amino]-(9CI)
2-amino-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylic acid methyl ester
1H-Pyrrole-2,4-dicarboxylicacid, 3-methyl-, 4-ethyl ester
1H-Pyrrole-2,4-dicarboxylicacid, 3-methyl-, 2-ethyl ester
Benzenamine,3-(trifluoromethyl)-, hydrochloride (1:1)
(R)-1-(1H-Benzimidazol-2-yl)ethylamine Hydrochloride
1-METHYL-1H-IMIDAZO[4,5-B]PYRIDINE-2-CARBOXALDEHYDE HYDROCHLORIDE
Xanthopterin Hydrate
Xanthopterin hydrate, an unconjugated pteridine compound, is the main component of the yellow granule in the Oriental hornet bear wings, produces a characteristic excitation/emission maximum at 386/456 nm[2]. Xanthopterin hydrate(XPT) causes renal growth and hypertrophy in rat[1]. Xanthopterin hydrate inhibits RNA synthesis[4]. Xanthopterin hydrate, an unconjugated pteridine compound, is the main component of the yellow granule in the Oriental hornet bear wings, produces a characteristic excitation/emission maximum at 386/456 nm[2]. Xanthopterin hydrate(XPT) causes renal growth and hypertrophy in rat[1]. Xanthopterin hydrate inhibits RNA synthesis[4].
5-(Ethylthio)-3-(Trifluoromethyl)-1H-1,2,4-Triazole
3-methyl-7,8-dihydroquinolin-5(6H)-one hydrochloride
(2R)-2-amino-3-(2,4-dihydroxyphenyl)propanoic acid
(2S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)propanoate
(3E)-3-[(1R,5R,6S)-5-hydroxy-7-oxabicyclo[4.1.0]heptan-2-ylidene]pyruvate
A 2-oxo monocarboxylic acid anion that is the conjugate base of (3E)-3-[(1R,5R,6S)-5-hydroxy-7-oxabicyclo[4.1.0]heptan-2-ylidene]pyruvic acid, obtained by deprotonation of the carboxy group.
(S)-2-Amino-3-(3-hydroxy-4-oxo-4H-pyridin-1-yl)propanoate
2-(Hydroxy-methoxy-phosphinoyl)oxyethylaminoformamidine
3-[(2Z,5R)-5-hydroxy-7-oxabicyclo[4.1.0]heptan-2-ylidene]-2-oxopropanoate
2-Amino-4-hydroxy-4-[hydroxy(methyl)phosphoryl]butanoic acid
Vanillylmandelate
A hydroxy monocarboxylic acid anion that is the conjugate base of vanillylmandelic acid.
(6S)-3,3-dimethyl-5,6-dihydro-4H-pyridine-2,6-dicarboxylate
3-[(2-hydroxyethyl)disulfanyl]-L-alanine
An S-substituted L-cysteine where the S-substituent is specified as (2-hydroxyethyl)sulfane.
2-AMINO-4,6-DINITROTOLUENE
An amino-nitrotoluene that is 4,6-dinitrotoluene substituted at position 2 by an amino group.
4-Amino-2,6-dinitrotoluene
An amino-nitrotoluene that is 2,6-dinitrotoluene substituted at position 4 by an amino group.
DL-AP5
The 5-phosphono derivative of 2-aminopentanoic acid; acts as an N-methyl-D-aspartate receptor antagonist. DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina[1][2][3].
L-dopa zwitterion
An amino acid zwitterion obtained from the transfer of a proton from the carboxy group to the amino group of L-dopa. Major microspecies at pH 7.3.
D-dopa zwitterion
An amino acid zwitterion obtained from the transfer of a proton from the carboxy group to the amino group of D-dopa. Major microspecies at pH 7.3.
Phosphoguanidinoacetic acid
A guanidinoacetate having a phospho group attached to the primary amino part of the guanidine moiety.
